Tyrone Bordenave
Internal Medicine · Inglewood, CANPI 1265543292
Payments from drug & device makers
Across 97 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$254
- AstraZeneca$244
- GSK$240
- Boehringer Ingelheim$217
- Mylan Specialty L.p.$86
- Sanofi-aventis U.S. LLC$77
- plus $640 from 14 others
What the payments were for
- Food & beverage$1,760100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $254 |
| AstraZeneca | 13 | $244 |
| GSK | 14 | $240 |
| Boehringer Ingelheim | 10 | $217 |
| Mylan Specialty L.p. | 4 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| AbbVie(2 entities) | 5 | $75 |
| Lilly USA, LLC | 4 | $65 |
| Novartis | 3 | $65 |
| Amarin Pharma, Inc. | 3 | $63 |
| Amgen | 2 | $56 |
| Arbor Pharmaceuticals, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $50 |
| Merck | 3 | $49 |
| Novo Nordisk | 2 | $43 |
| Astellas Pharma US Inc | 2 | $37 |
| Circassia Inc. | 2 | $26 |
| Bayer | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Organon | 1 | $16 |
How this compares
$1,760 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 33 | $43,091 |
| JardianceEmpagliflozin | 25 | $20,856 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,688 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $10,450 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $8,558 |
| LantusInsulin Glargine,hum.Rec.Anlog | 15 | $2,557 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $2,298 |
| Atorvastatin Calcium | 149 | $1,442 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 13 | $1,131 |
| Amlodipine Besylate | 153 | $1,107 |
| Celecoxib | 16 | $1,098 |
| Metformin Hcl | 94 | $791 |
| Lisinopril | 80 | $722 |
| Benazepril-HydrochlorothiazideBenazepril/Hydrochlorothiazide | 17 | $695 |
| Gabapentin | 49 | $629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $49 | $43,09133 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $217 | $29,41338 claims |
| GSKTrelegy Ellipta | $240 | $14,68823 claims |
| Sanofi-aventis U.S. LLCLantus | $77 | $2,55715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Inglewood
- Soheil HekmatInglewood$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.